Margherita Fogliano
Precision genome editing holds immense promise for the treatment of genetic disorders, but efficient in vivo delivery of CRISPR-Cas9 components remains a formidable challenge. This article explores the development and application of targeted nanoparticles as a delivery platform for the CRISPR-Cas9 system. We discuss the design, optimization, and in vivo testing of nanoparticles tailored to specific cell types and tissues. The integration of nanotechnology and genome editing not only enhances the precision and efficiency of genome modifications but also paves the way for potential therapeutic breakthroughs.
Ali Tafaghod
The study of single-cell heterogeneity is a fundamental aspect of understanding complex biological systems. This article explores the transformative capabilities of quantitative Imaging Flow Cytometry (qIFC) in unraveling the intricacies of single-cell analysis. We discuss the principles, instrumentation, and data analysis techniques associated with qIFC, emphasizing its capacity to provide quantitative and spatial information at the single-cell level. This technology enables comprehensive investigations into cell populations, revealing hidden phenotypic diversity, dynamic responses, and subcellular features. The integration of qIFC is poised to advance our knowledge of cellular biology, immunology, and disease mechanisms.
Tarek Porro
The human gut microbiota plays a pivotal role in drug metabolism, impacting drug efficacy and safety. This article delves into the burgeoning field of gut microbiota-mediated drug metabolism and its implications for personalized medicine. We explore the mechanisms underlying microbiotamediated transformations of pharmaceuticals, their influence on drug bioavailability, and their potential to modulate individual drug responses. By elucidating the interplay between gut microbes and drugs, we uncover new avenues for tailoring drug therapies to individual patients, ultimately enhancing treatment outcomes.
Janosch Kraft
High-throughput proteomic profiling has become a pivotal tool in identifying potential biomarkers for various diseases. This article reviews recent advancements in proteomic technologies and their application in biomarker discovery. We discuss the challenges associated with data analysis and integration and explore strategies to enhance the sensitivity and specificity of biomarker identification. By harnessing the power of mass spectrometry, machine learning, and bioinformatics, researchers are making significant strides towards revolutionizing disease diagnosis and personalized treatment strategies.
Khare Soumya1*, Chatterjee Tanushree1, Gupta Shailendra2 y Patel Ashish3
La beta talasemia es un trastorno en el que el cuerpo no puede sintetizar la subunidad beta de la hemoglobina debido a mutaciones perjudiciales en el gen de la β-globina que provocan una producción insuficiente de hemoglobina adulta (HbA). La hemoglobina fetal (HbF), que se compone de dos subunidades α y dos γ, se ha identificado como un posible sustituto de la HbA con gran importancia clínica en pacientes con β-talasemia. Sin embargo, en las etapas de desarrollo, la expresión de HbF se reduce gradualmente y es superada por la HbA. Nuestra investigación descubrió que la investigación de la expresión sanguínea y su relación con los DEG puede ayudar a dilucidar el papel de estos DEG en la progresión de la beta talasemia, y un estudio de secuenciación de ARN indicó que el gen de la β-globina está regulado a la baja. Hay 200 genes que se expresan de forma diferente en pacientes con β talasemia en comparación con controles sanos, así como dos genes clave. KLF1 y MDM2 son dos genes diana potenciales para pacientes con beta talasemia que podrían emplearse como indicadores de diagnóstico. Los genes expresados ??diferencialmente incluyen genes involucrados en la biosíntesis del hemo, la unión del hemo, la homeostasis de los eritrocitos, la unión de iones de hierro, la diferenciación de los eritrocitos, el transporte de gases y la respuesta a los procesos metabólicos de las especies de oxígeno, y otros procesos celulares. Sin embargo, se necesitan estudios funcionales para confirmar su relevancia propuesta en la beta talasemia.